Quarterly report
Open the filing on sec.gov
Summit Therapeutics Inc. (SMMT)
Nasdaq: SMMT · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 2014
The companyfiscal 2024, as filed
Revenue$0.00
Net income-$221M+64.0%
Earnings per share$-0.31+68.7%
Operating cash flow-$142M-85.1%
Cash$105M+47.3%
Debtn/a
Shareholders’ equity$389M+400.4%
Shares, diluted718.5M+16.0%
Return on equity-163.9%
The recordfrom its filings
Filings in 202652
Newest filingNov 4 · 10-Q
Annual reportFeb 23, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$0.00
Insider buys, 12 months$115M
Patents granted5
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Net income -$833MCash from operations -$525Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Resale prospectus supplement
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
AstraZeneca puts $2 billion into Summit weeks before its FDA date
Read the article
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.